Liposomal Doxorubicin in Treating Patients With Advanced or Recurrent Endometrial Cancer
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00005861. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Evaluation of Doxil as First-Line Therapy of Advanced or Recurrent Endometrial Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of liposomal doxorubicin in treating women who have recurrent, stage III, or stage IV endometrial cancer.
Study identification
- NCT ID
- NCT00005861
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2000 (Type not available)
- Primary completion
- Aug 2005 (Actual)
- Completion
- Not listed
- Last update posted
- Jun 10, 2013
Started 2000
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Chao Family Comprehensive Cancer Center | Orange | California | 92868 | — |
| Indiana University Cancer Center | Indianapolis | Indiana | 46202-5289 | — |
| Holden Comprehensive Cancer Center | Iowa City | Iowa | 52242-1009 | — |
| New England Medical Center Hospital | Boston | Massachusetts | 02111 | — |
| University of Mississippi Medical Center | Jackson | Mississippi | 39216-4505 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Duke Comprehensive Cancer Center | Durham | North Carolina | 27710 | — |
| Comprehensive Cancer Center at Wake Forest University | Winston-Salem | North Carolina | 27157-1082 | — |
| Arthur G. James Cancer Hospital - Ohio State University | Columbus | Ohio | 43210-1240 | — |
| Brookview Research, Inc. | Nashville | Tennessee | 37203 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00005861, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 10, 2013 · Synced Nov 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.